Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-23
DOI
10.1038/s41585-022-00676-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations.
- (2022) Yasser Ged et al. JOURNAL OF CLINICAL ONCOLOGY
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis
- (2022) Selcuk Erdem et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
- (2022) Börje Ljungberg et al. EUROPEAN UROLOGY
- DNA repair defects in cancer and therapeutic opportunities
- (2022) Jessica L. Hopkins et al. GENES & DEVELOPMENT
- Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
- (2022) Yann-Alexandre Vano et al. LANCET ONCOLOGY
- Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
- (2022) Nazli Dizman et al. NATURE MEDICINE
- Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
- (2022) Robert J Motzer et al. Journal for ImmunoTherapy of Cancer
- Identification of CXCL10 as a Prognostic Biomarker for Clear Cell Renal Cell Carcinoma
- (2022) Genyi Qu et al. Frontiers in Oncology
- The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
- (2022) Marzia Del Re et al. Journal of Translational Medicine
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
- (2021) Audrey Simonaggio et al. Cancers
- Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
- (2021) David A. Braun et al. CANCER CELL
- Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?
- (2021) Annalisa Guida et al. CANCER TREATMENT REVIEWS
- Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
- (2021) Alice Indini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
- (2021) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
- (2021) Ziad Bakouny et al. Nature Communications
- Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
- (2021) Yeon Jeong Kim et al. Scientific Reports
- Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma
- (2021) Aly-Khan A. Lalani et al. JAMA Oncology
- Seeing the forest for the trees—single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer
- (2021) Mei Yee Koh et al. CANCER CELL
- 688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features
- (2021) P.M. Coelho Barata et al. ANNALS OF ONCOLOGY
- 693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy
- (2021) M. Soleimani et al. ANNALS OF ONCOLOGY
- 689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
- (2021) L. Kinget et al. ANNALS OF ONCOLOGY
- 660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
- (2021) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- 79P SETD2 a potential tissue-agnostic predictive biomarker for ICIs in solid tumors
- (2021) Y. Chen et al. ANNALS OF ONCOLOGY
- 692P Characterization of the tumor immune microenvironment in early-stage clear cell renal cell carcinoma (ccRCC): Prognostic value of an M0-macrophage enriched subtype
- (2021) M. Farha et al. ANNALS OF ONCOLOGY
- Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
- (2021) Francesco Massari et al. EUROPEAN JOURNAL OF CANCER
- Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis
- (2021) Alessandro Rizzo et al. Immunotherapy
- Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence
- (2021) Alessandro Rizzo et al. Immunotherapy
- The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
- (2021) Andrea Marchetti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests
- (2021) Raimonda Kubiliute et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
- (2021) Chung-Han Lee et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer
- (2021) Michela Murdocca et al. Cancers
- Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
- (2021) Veronica Mollica et al. Cancers
- The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma
- (2021) Jerred P. Pletcher et al. Frontiers in Oncology
- Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
- (2021) T.K. Choueiri et al. ESMO Open
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
- (2021) Lewis Au et al. CANCER CELL
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
- (2021) Elena V. Demidova et al. EUROPEAN UROLOGY
- The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma
- (2021) Masayuki Hagiwara et al. EUROPEAN UROLOGY
- eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer
- (2021) Alessandra I.G. Buma et al. LUNG CANCER
- Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis
- (2021) Roy Mano et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Involvement of PBRM1 in VHL disease‑associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway
- (2021) Sophie Gad et al. Oncology Letters
- Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
- (2021) Robert J. Motzer et al. JAMA Oncology
- Treatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination Therapy
- (2021) Vishal Navani et al. JAMA Oncology
- Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models
- (2020) Steven N. Seyedin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Combining microenvironment normalization strategies to improve cancer immunotherapy
- (2020) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12
- (2020) Patricia González-Rodríguez et al. Cell Death & Disease
- Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes
- (2020) Franziska Büscheck et al. Oncotarget
- Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma
- (2020) Ninadh M. D’Costa et al. Scientific Reports
- Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Fausto Petrelli et al. Cancers
- Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
- (2020) Maxime Frelaut et al. BIODRUGS
- Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer
- (2020) Biagio Ricciuti et al. CLINICAL CANCER RESEARCH
- Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
- (2020) Alessio Cortellini et al. EUROPEAN JOURNAL OF CANCER
- Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
- (2020) Lisa Derosa et al. EUROPEAN UROLOGY
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
- (2020) David A. Braun et al. NATURE MEDICINE
- Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
- (2020) Zia Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
- (2020) Mary A. Wood et al. Genome Medicine
- Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors
- (2020) Sarah Abou Alaiwi et al. Cancer Immunology Research
- Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
- (2020) Matthew Kyle Labriola et al. Journal for ImmunoTherapy of Cancer
- CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
- (2020) Quan Zhou et al. Journal for ImmunoTherapy of Cancer
- Tumor mutational burden and immune signatures interplay in renal cell carcinoma
- (2020) Evgeny Yakirevich et al. Annals of Translational Medicine
- BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
- (2020) Nicolas Epaillard et al. BULLETIN DU CANCER
- Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
- (2020) Brian I. Rini et al. EUROPEAN UROLOGY
- The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy
- (2020) Yongchang Lai et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes
- (2020) Pier Vitale Nuzzo et al. NATURE MEDICINE
- DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
- (2020) Yasser Ged et al. Journal for ImmunoTherapy of Cancer
- Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
- (2020) Nazli Dizman et al. Journal for ImmunoTherapy of Cancer
- The CCL5/CCR5 Axis in Cancer Progression
- (2020) Donatella Aldinucci et al. Cancers
- The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
- (2020) Alberto Carretero-González et al. Cancers
- Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
- (2020) Alessandra Raimondi et al. Frontiers in Oncology
- Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma
- (2020) Chun Loo Gan et al. CANCER JOURNAL
- Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
- (2020) Nizar M. Tannir et al. CLINICAL CANCER RESEARCH
- Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review
- (2020) Eline Janssens et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
- (2020) Roberto Iacovelli et al. EUROPEAN JOURNAL OF CANCER
- Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors
- (2020) Nicholas J. Salgia et al. EUROPEAN UROLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Targeting the HIF2–VEGF axis in renal cell carcinoma
- (2020) Toni K. Choueiri et al. NATURE MEDICINE
- Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
- (2020) Matthew D. Tucker et al. Cancers
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
- (2020) Robert J. Motzer et al. CANCER CELL
- How to manage patients with corticosteroids in oncology in the era of immunotherapy?
- (2020) Mihaela Aldea et al. EUROPEAN JOURNAL OF CANCER
- Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
- (2020) Elizabeth C. Paver et al. PATHOLOGY
- Correlate tumor mutation burden with immune signatures in human cancers
- (2019) Xiaosheng Wang et al. BMC IMMUNOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial
- (2019) A. Ari Hakimi et al. Cancer Discovery
- The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma
- (2019) Asim Amin et al. Frontiers in Immunology
- Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy
- (2019) Alessia Cimadamore et al. Cancers
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma
- (2019) David D. Stenehjem et al. PLoS One
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).
- (2019) A. Ari Hakimi et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.
- (2019) Nizar M. Tannir et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Infiltration in Renal Cell Carcinoma
- (2019) Shichao Zhang et al. CANCER SCIENCE
- Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors
- (2019) Annelies Verbiest et al. Clinical Genitourinary Cancer
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
- (2019) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
- (2019) Elena Verzoni et al. Journal for ImmunoTherapy of Cancer
- BAP1 in solid tumors
- (2019) Vincenzo Di Nunno et al. Future Oncology
- Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy
- (2019) Isabel Heidegger et al. Frontiers in Oncology
- Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies
- (2019) Alessia Cimadamore et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
- (2019) David A. Braun et al. JAMA Oncology
- Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath
- (2019) R de Vries et al. ANNALS OF ONCOLOGY
- 910PDEfficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
- (2019) T K Choueiri et al. ANNALS OF ONCOLOGY
- Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
- (2019) Ludovic Fournel et al. CANCER LETTERS
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
- (2019) David J. Clark et al. CELL
- Toward a genome-based treatment landscape for renal cell carcinoma
- (2019) Francesco Massari et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Mechanisms Controlling PD-L1 Expression in Cancer
- (2019) Jong-Ho Cha et al. MOLECULAR CELL
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study
- (2019) Alejandro Sanchez et al. LANCET ONCOLOGY
- Unlocking the secret of the obesity paradox in renal tumours
- (2019) Matteo Santoni et al. LANCET ONCOLOGY
- Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
- (2019) Dylan J. Martini et al. ONCOLOGIST
- Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
- (2019) Lucía Carril-Ajuria et al. Cancers
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Safety and Efficacy of Nivolumab for Metastatic Renal Cell Carcinoma: Real-World Results From an Expanded Access Program
- (2018) Ugo De Giorgi et al. BJU INTERNATIONAL
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
- (2018) Samra Turajlic et al. CELL
- The Role of Circulating Tumor DNA in Renal Cell Carcinoma
- (2018) Paulo G. Bergerot et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer
- (2018) Liu Yang et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Pseudoprogression and hyperprogression after checkpoint blockade
- (2018) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC).
- (2018) Manuel C. Maia et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST
- (2018) Alessandro Inno et al. TUMORI
- Prognostic factors and prognostic models for renal cell carcinoma: a literature review
- (2018) Tobias Klatte et al. WORLD JOURNAL OF UROLOGY
- An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors
- (2018) Tao Wang et al. Cancer Discovery
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
- (2018) Christopher J. Ricketts et al. Cell Reports
- Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
- (2018) Kristina Buder-Bakhaya et al. Frontiers in Immunology
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
- (2018) Aly-Khan A. Lalani et al. Journal for ImmunoTherapy of Cancer
- The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST
- (2018) Alessandro Inno et al. TUMORI JOURNAL
- The comings and goings of PARP-1 in response to DNA damage
- (2018) John M. Pascal DNA REPAIR
- Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
- (2018) Xin Gao et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
- (2018) Dominick Bossé et al. JOURNAL OF CLINICAL ONCOLOGY
- Accuracy and Methodologic Challenges of Volatile Organic Compound–Based Exhaled Breath Tests for Cancer Diagnosis
- (2018) George B. Hanna et al. JAMA Oncology
- 869PDTumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk
- (2018) B Beuselinck et al. ANNALS OF ONCOLOGY
- Clinical significance of the mutational landscape and fragmentation of circulating‐tumor DNA in renal cell carcinoma
- (2018) Yoshiyuki Yamamoto et al. CANCER SCIENCE
- Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
- (2018) Martin H Voss et al. LANCET ONCOLOGY
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
- (2018) Ziming Wang et al. NATURE MEDICINE
- Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study
- (2018) Anas M. Saad et al. Clinical Genitourinary Cancer
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
- (2017) Sabrina Lagniau et al. Oncotarget
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
- (2016) Richard W. Joseph et al. JOURNAL OF UROLOGY
- Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
- (2016) Mark Bi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
- (2015) B. Beuselinck et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
- (2015) Katia R M Leite et al. Diagnostic Pathology
- Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma
- (2015) Roberto Iacovelli et al. EUROPEAN UROLOGY
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
- (2015) Jenny J Ko et al. LANCET ONCOLOGY
- Breath carbonyl compounds as biomarkers of lung cancer
- (2015) Mingxiao Li et al. LUNG CANCER
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma
- (2015) Francesco Piva et al. Oncotarget
- Oxidative stress and volatile organic compounds: interplay in pulmonary, cardio-vascular, digestive tract systems and cancer
- (2015) Bogdan Calenic et al. Open Chemistry
- Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma
- (2013) Richard W. Joseph et al. CANCER
- Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
- (2013) A. A. Hakimi et al. CLINICAL CANCER RESEARCH
- CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling
- (2013) Taku Kato et al. CYTOKINE
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
- (2013) Payal Kapur et al. LANCET ONCOLOGY
- The Nature of Nurture: Refining the Definition of the Exposome
- (2013) Gary W. Miller et al. TOXICOLOGICAL SCIENCES
- Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma
- (2013) JingJing Wan et al. UROLOGIA INTERNATIONALIS
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review
- (2012) Kim DG van de Kant et al. RESPIRATORY RESEARCH
- Autocrine CCL5 Signaling Promotes Invasion and Migration of CD133+Ovarian Cancer Stem-Like Cells via NF-κB-Mediated MMP-9 Upregulation
- (2012) Haixia Long et al. STEM CELLS
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
- (2011) M. Bianchi et al. ANNALS OF ONCOLOGY
- The scent of disease: volatile organic compounds of the human body related to disease and disorder
- (2011) M. Shirasu et al. JOURNAL OF BIOCHEMISTRY
- PARP inhibitors in cancer: moving beyond BRCA
- (2011) Melinda L Telli LANCET ONCOLOGY
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
- A review of PARP inhibitors: from bench to bedside
- (2010) C. Underhill et al. ANNALS OF ONCOLOGY
- Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB
- (2010) Johanna C. Scheuermann et al. NATURE
- Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma
- (2009) Min-Han Tan et al. UROLOGY
- VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
- (2009) C. Lance Cowey et al. Current Oncology Reports
- CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
- (2008) Chun-Yin Huang et al. BIOCHEMICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More